DxTerity Diagnostics

The company is combining digital recruiting methods with at-home sample collection to speed up the study process.

The Biomedical Advanced Research and Development Authority aims to produce at least two US Food and Drug Administration-cleared tests.

DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.

The firm plans to seek Emergency Use Authorization for the 18-gene panel and will subsequently submit it to the FDA for full approval.

The firm will use the money from SWK Funding to commercialize its DxDirect genomic testing platform and its DxCollect MicroCollection Device.

The additional funds bring the total contract to $43 million over approximately eight years.

With eight independently programmable amplification wells, the firm's portable PCR platform is now in small-scale production.

Molecular diagnostics company DxTerity Diagnostics was recently awarded a $280,000 Small Business Innovation Research contract from the National Cancer Institute to develop a test for susceptibility to radiation sickness during cancer treatment.

DxTerity Diagnostics has developed a rapid assay for analyzing gene expression of as many as 100 genes directly from small amounts of formalin-fixed, paraffin-embedded clinical samples without prior RNA extraction.

Pages

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.